In vivo Raman spectroscopy discriminates between FLG loss-of-function carriers vs wild-type in day 1-4 neonates

Chaoimh, Carol Ní; Nico, C.; Puppels, Gerwin J.; Wong, Xuan Fei Colin Cornelius; Common, John E.A.; Irvine, Alan D.; Hourihane, Jonathan

doi:10.1016/j.anai.2020.01.022

Cited by 10 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18,116,117 Curiously, despite some reports on the correlation of the ''itch cytokine,'' IL-31, with disease severity, 62,118 more evidence is accumulating on the lack of such correlation. 102,[119][120][121] Predictive biomarkers Tissue biomarkers predicting disease onset include TARC and IgE in the umbilical cords of newborns 122,123 and natural moisturizing factor levels in neonates' skin, 124 which are known to strongly correlate with transepidermal water loss, 23 another predictor of AD development in newborns. 125,126 Moisturizers can prevent AD in high-risk infants, 127 and were shown to alter skin microbiome and reduce skin pH in this population.…”

Section: Biomarkers That Failed To Show Consistent Correlation With Smentioning

confidence: 99%

Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council

Renert‐Yuval

Thyssen

Bissonnette

et al. 2021

Journal of Allergy and Clinical Immunology

166

210

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic challenge with increasingly recognized different phenotypes among variable patient populations. Because therapeutic response may vary on the basis of heterogeneous clinical and molecular phenotypes, a shift toward precision medicine approaches may improve AD management. Herein, we will consider biomarkers as potential instruments in the toolbox of precision medicine in AD and will review the process of biomarker development and validation, the opinion of AD experts on the use of biomarkers, types of biomarkers, encompassing biomarkers that may improve AD diagnosis, biomarkers reflecting disease severity, and those potentially predicting AD development, concomitant atopic diseases, or therapeutic response, and current practice of biomarkers in AD. We found that chemokine C-C motif ligand 17/thymus and activation-regulated chemokine, a chemoattractant of T H 2 cells, has currently the greatest evidence for robust correlation with AD clinical severity, at both baseline and during therapy, by using the recommendations, assessment, development, and evaluation approach. Although the potential of biomarkers in AD is yet to be fully elucidated, due to the complexity of the disease, a comprehensive approach taking into account both clinical and reliable, AD-specific biomarker evaluations would further facilitate AD research and improve patient management.

show abstract

Section: Biomarkers That Failed To Show Consistent Correlation With Smentioning

confidence: 99%

Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council

Renert‐Yuval

Thyssen

Bissonnette

et al. 2021

Journal of Allergy and Clinical Immunology

166

210

View full text Add to dashboard Cite

show abstract

“… 147 , 148 This technology was uses to show reduced levels of NMF in AD children who carry one of the FLG null mutation(s), making this a potential assay to identify carriers of FLG mutations. 134 , 149 Electrical impedance spectroscopy (EIS) , is a new non-invasive method currently used for the detection of melanoma and uses alternating currents of various frequencies to measure overall resistance within a tissue. 150 EIS has recently been used to evaluate skin barrier in AD subjects.…”

Section: Methods To Assess Skin Barrier In Vivomentioning

confidence: 99%

Skin barrier defects in atopic dermatitis: From old idea to new opportunity

Yoshida

Beck

Benedetto

2022

Allergology International

View full text Add to dashboard Cite

“…It can be measured with a device containing two moisture sensors and two thermometers that calculate the rate of evaporation. All subjects will also have measurements of natural moisturizing factor (NMF) via Raman spectroscopy [ 38 ]. A skin sample using tape stripping will be taken for inflammatory cytokine analysis.…”

Section: Methodsmentioning

confidence: 99%

“…In healthy skin, filaggrin is degraded by proteases into natural moisturizing factors (NMF). Skin barrier function can be assessed by TEWL or by NMF measured by Raman spectroscopy, with reference data previously published by INFANT [ 37 , 38 ]. Higher TEWL and lower NMF levels are associated with more severe AD [ 39 , 40 ].…”

Section: Introductionmentioning

confidence: 99%

Study protocol: assessing SleeP IN infants with early-onset atopic Dermatitis by Longitudinal Evaluation (The SPINDLE study)

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Atopic dermatitis (AD) is the most common chronic inflammatory skin condition in childhood. Most (50-60%) children with AD report sleep disturbance, which is secondary to itch, dry skin, inflammation, and abnormal circadian rhythm. Sleep is essential for brain development, learning, and growth. Sleep disruption in early life is associated with cognitive and psychological dysfunction in later life. The aim of this study is to describe in detail the sleep architecture of infants with early-onset atopic dermatitis (AD), compared to controls, by using EEG polysomnography, sleep actigraphy, and parental reporting. Methods This observational study will recruit six- to eight-month old infants with moderate to severe AD and age-matched control infants who do not have AD. At six-eight months diurnal sleep electroencephalography and polysomnography will be performed in our research center. Nocturnal sleep actigraphy will be performed at home for five consecutive nights at six-eight months and 12 months. Between six and 12 months, monthly questionnaires will capture data on quantitative sleep and parental sleep. Skin barrier and immune profiles will be captured at six-eight and 12 months. AD will be assessed using standardized severity assessment tools and treated according to protocol. A neurodevelopmental assessment will be performed at 18 months to assess cognition and behaviour. An estimated sample size of 50 participants in each group is required to power the primary outcome of disturbed macrostructure of sleep and secondary outcomes of disturbed microstructure of sleep, and disturbed parental sleep, assuming an attrition rate of 60%. Potential confounding factors which will be controlled for in the data analysis will include parental educational level, parental depression, feeding practice, and number of siblings. Discussion This study will provide a rich analysis of sleep in infants with AD in the first year of life using detailed electroencephalography, novel actigraphy techniques, and longitudinal parent-reported data. It may provide guidance on the optimal treatment of AD to prevent or reduce sleep disruption. Trial registration clinicaltrials.govNCT05031754, retrospectively registered on September 2nd, 2021.

show abstract

In vivo Raman spectroscopy discriminates between FLG loss-of-function carriers vs wild-type in day 1-4 neonates

Cited by 10 publications

References 14 publications

Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council

Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council

Skin barrier defects in atopic dermatitis: From old idea to new opportunity

Study protocol: assessing SleeP IN infants with early-onset atopic Dermatitis by Longitudinal Evaluation (The SPINDLE study)

Contact Info

Product

Resources

About